[go: up one dir, main page]

AR089005A1 - Vacunas contra el virus de la influenza y sus usos - Google Patents

Vacunas contra el virus de la influenza y sus usos

Info

Publication number
AR089005A1
AR089005A1 ARP120104458A ARP120104458A AR089005A1 AR 089005 A1 AR089005 A1 AR 089005A1 AR P120104458 A ARP120104458 A AR P120104458A AR P120104458 A ARP120104458 A AR P120104458A AR 089005 A1 AR089005 A1 AR 089005A1
Authority
AR
Argentina
Prior art keywords
polypeptides
stem
influenza hemagglutinin
influenza virus
vaccines against
Prior art date
Application number
ARP120104458A
Other languages
English (en)
Inventor
Willem Meijberg Jan
Impagliazzo Antonietta
Vogels Ronald
Heinz Edward Friesen Robert
Alard Philippe
Loverix Stefan
Radoevi Katarina
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of AR089005A1 publication Critical patent/AR089005A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polipéptidos que comprenden dominios del tallo de la hemaglutinina de la influenza. En particular, dichos polipéptidos comprenden (a) un dominio HA1 de la hemaglutinina de la influenza, que comprende un segmento del tallo HA1 del extremo N, unido a través de enlaces covalentes a una secuencia conectora de 0 - 50 aminoácidos, que a su vez está unida a un segmento del tallo HA1 del extremo C, y (b) un dominio HA2 de la hemaglutinina de la influenza en el que se han mutado uno o más aminoácidos. Ácidos nucleicos que codifican dichos polipéptidos. Composiciones que comprenden polipéptidos como los que se han descripto y/o moléculas de ácidos nucleicos que los codifican. Métodos para usarlos, particularmente en la detección, la prevención y/o el tratamiento de la influenza.
ARP120104458A 2011-11-28 2012-11-28 Vacunas contra el virus de la influenza y sus usos AR089005A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11191009 2011-11-28
EP11191003 2011-11-28
EP12166268 2012-05-01
US201261720281P 2012-10-30 2012-10-30

Publications (1)

Publication Number Publication Date
AR089005A1 true AR089005A1 (es) 2014-07-23

Family

ID=48534691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104458A AR089005A1 (es) 2011-11-28 2012-11-28 Vacunas contra el virus de la influenza y sus usos

Country Status (20)

Country Link
US (3) US9452211B2 (es)
EP (2) EP3566714A1 (es)
JP (1) JP6294828B2 (es)
KR (1) KR101983989B1 (es)
CN (1) CN104066446B (es)
AR (1) AR089005A1 (es)
AU (1) AU2012343981B2 (es)
BR (1) BR112014012681A8 (es)
CA (1) CA2857087C (es)
EA (1) EA033386B1 (es)
HK (1) HK1199211A1 (es)
IL (1) IL232780A (es)
IN (1) IN2014CN04742A (es)
MX (1) MX357009B (es)
MY (1) MY170927A (es)
PH (1) PH12014501118B1 (es)
SG (1) SG11201402633UA (es)
TW (1) TWI618715B (es)
WO (1) WO2013079473A1 (es)
ZA (1) ZA201404797B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
KR20120132506A (ko) 2010-02-18 2012-12-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
WO2013177444A2 (en) * 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014273173B2 (en) * 2013-05-30 2018-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EP3805254A1 (en) * 2013-08-03 2021-04-14 Calder Biosciences Inc. Methods of making and using influenza virus hemagglutinin complexes
EP3137487B1 (en) * 2014-05-01 2021-03-03 Indian Institute of Science Polypeptides for generating anti-influenza antibodies and uses thereof
NZ727024A (en) 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CN107074912B (zh) * 2014-07-10 2021-10-29 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
MX378904B (es) * 2014-07-10 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
EP3294753A1 (en) * 2015-05-11 2018-03-21 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
EP3344288A1 (en) * 2015-09-02 2018-07-11 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3035443A1 (en) * 2016-09-02 2018-03-08 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
CN110325208A (zh) * 2016-09-16 2019-10-11 威克斯技术公司 针对流感的疫苗接种的组合物和方法
EP3528827A4 (en) * 2016-10-21 2020-11-04 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019100147A1 (en) * 2017-11-22 2019-05-31 Her Majesty the Queen in the Right of Canada as represented by the Minister of Health Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
EP3730620A4 (en) 2017-12-21 2022-01-05 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
RS63526B1 (sr) * 2018-01-23 2022-09-30 Janssen Vaccines & Prevention Bv Vakcine za virus gripa i njihove upotrebe
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CA3103849A1 (en) 2018-06-27 2020-01-02 Medicago Inc. Influenza virus hemagglutinin mutants
JP2022530439A (ja) * 2019-04-25 2022-06-29 ヤンセン ファッシンズ アンド プリベンション ベーフェー 組換えインフルエンザ抗原
JP2022547107A (ja) 2019-09-05 2022-11-10 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
MX2022004570A (es) * 2019-10-15 2022-05-06 Janssen Vaccines & Prevention Bv Vacunas contra el virus de la gripe y usos de estas.
TWI870591B (zh) * 2020-05-08 2025-01-21 中央研究院 嵌合流感疫苗
US20230310575A1 (en) * 2020-09-02 2023-10-05 St. Jude Children's Research Hospital, Inc. Hemagglutinin Modifications for Improved Influenza Vaccine Production
CN116528893A (zh) * 2020-09-07 2023-08-01 英特维特国际股份有限公司 用于ha抗体阳性靶标的ha茎疫苗
EP4362974A1 (en) * 2021-06-28 2024-05-08 GlaxoSmithKline Biologicals S.A. Novel influenza antigens
WO2024038382A1 (en) * 2022-08-16 2024-02-22 Seqirus Inc. Modified influenza viruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116874607B (zh) * 2023-06-09 2024-12-10 山西高等创新研究院 一种h9亚型禽流感重组嵌合疫苗及其制备方法
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用
WO2025038983A1 (en) * 2023-08-17 2025-02-20 Colorado State University Research Foundation Inactivated whole virion vaccine against influenza and methods of use thereof
WO2025149907A1 (en) * 2024-01-08 2025-07-17 Seqirus Inc. Influenza vaccines

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
CA2418977C (en) 2000-08-10 2011-01-18 Crucell Holland B.V. Gene delivery vectors with cell type specificity for primary human chondrocytes
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
AU2003271737B2 (en) 2002-04-25 2007-04-19 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
SI1497440T1 (sl) 2002-04-25 2009-02-28 Crucell Holland Bv Stabilni adenovirusni vektorji in postopki za njihovo propagacijo
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
BRPI0414670A (pt) 2003-10-02 2006-11-21 Crucell Holland Bv método para preparar uma célula, célula, métodos para fornecer uma célula e para gerar uma batelada de adenovìrus recombinante, molécula recombinante, conjunto de pelo menos duas moléculas de ácido nucleico, e, sistema de empacotamento
WO2006053871A2 (en) 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
JP5161882B2 (ja) * 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
WO2010117786A1 (en) * 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
AU2010247530B2 (en) * 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
US9708373B2 (en) * 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EA027054B1 (ru) 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
CA2857087C (en) 2011-11-28 2021-05-25 Crucell Holland B.V. Influenza virus vaccines and uses thereof
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
WO2013132007A1 (en) 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CA2884388A1 (en) 2012-09-27 2014-04-03 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof
AU2014273173B2 (en) 2013-05-30 2018-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
CN107074912B (zh) 2014-07-10 2021-10-29 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
MX378904B (es) 2014-07-10 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.

Also Published As

Publication number Publication date
MY170927A (en) 2019-09-19
CA2857087C (en) 2021-05-25
MX2014006396A (es) 2014-07-22
KR20140099515A (ko) 2014-08-12
IN2014CN04742A (es) 2015-09-18
EP2785372B1 (en) 2019-06-19
HK1199211A1 (en) 2015-06-26
CN104066446B (zh) 2017-10-03
TW201329101A (zh) 2013-07-16
US20140357845A1 (en) 2014-12-04
EP3566714A1 (en) 2019-11-13
IL232780A0 (en) 2014-07-31
EP2785372A1 (en) 2014-10-08
AU2012343981B2 (en) 2017-09-07
EA033386B1 (ru) 2019-10-31
US20160362455A1 (en) 2016-12-15
PH12014501118A1 (en) 2014-08-04
MX357009B (es) 2018-06-22
PH12014501118B1 (en) 2019-03-01
KR101983989B1 (ko) 2019-05-31
US20160355553A1 (en) 2016-12-08
JP2015502353A (ja) 2015-01-22
US9969778B2 (en) 2018-05-15
NZ625973A (en) 2016-09-30
BR112014012681A8 (pt) 2017-06-20
EA201491051A1 (ru) 2015-04-30
CN104066446A (zh) 2014-09-24
IL232780A (en) 2017-09-28
US9452211B2 (en) 2016-09-27
WO2013079473A1 (en) 2013-06-06
BR112014012681A2 (pt) 2017-06-13
JP6294828B2 (ja) 2018-03-14
ZA201404797B (en) 2022-03-30
SG11201402633UA (en) 2014-09-26
AU2012343981A1 (en) 2014-07-10
CA2857087A1 (en) 2013-06-06
TWI618715B (zh) 2018-03-21

Similar Documents

Publication Publication Date Title
AR089005A1 (es) Vacunas contra el virus de la influenza y sus usos
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
CL2019001000A1 (es) Proteínas de fusión fc heterodiméricas il15/il15ralfa
PE20170290A1 (es) Vacunas contra virus de influenza y usos de las mismas
CO6680702A2 (es) Péptido o complejo péptido que se une a integrina alfa 2 y metodos y sus usos que implican a los mismos
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
CL2016001405A1 (es) A peptide mixture
BR112015030582A2 (pt) Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
MX2019001215A (es) Metodos y composiciones para la expresion genica en plantas.
EA201592306A1 (ru) Вакцины против вируса гриппа и их применения
MX384363B (es) Nuevos polipéptidos de unión específica y usos de los mismos.
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
MX390924B (es) Detergentes y agentes de limpieza que comprenden una combinación de amilasa y proteasa.
NI201700156A (es) Péptidos lipidados resistentes a proteasas
AR102061A1 (es) Genes de chromobacterium subtsugae
MX2018001298A (es) Agente inductor de inmunidad.
CY1123664T1 (el) Εμβολιο
CU20140061A7 (es) Vacunas contra virus influenza y sus usos
SG10201908920QA (en) Influenza virus vaccines and uses thereof
IL249704B (en) Influenza virus vaccines and uses thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure